Studies from other laboratories showed that increased level of intracellular NAD+ enhanced the activities of SIRT1 and SIRT3 33, which in turn, suppressed cardiac hypertrophy through the activation of Foxo3a‐dependent antioxidant defence mechanism 34. The gene discussed is SIRT3; the disease is cardiac hypertrophy.